TMCnet News

HOOKIPA Pharma to Present at SVB Leerink's CybeRx Series Vaccine Forum
[September 16, 2020]

HOOKIPA Pharma to Present at SVB Leerink's CybeRx Series Vaccine Forum


NEW YORK and VIENNA, Austria, Sept. 16, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate and present at SVB Leerink’s CybeRx Series: Vaccine Forum, taking place September 23 – 24, 2020:

  • HOOKIPA Fireside Chat: Wednesday, September 23rd at 12:00 PM ET with Joern Aldag (CEO) and Igor Matushansky (CMO)

About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that reprograms the body’s immune system.

HOOKIPA’s proprietary arenavirus-based technologies, non-replicating (VaxWave®) and replicating (TheraT®), induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s “off-the-shelf” viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administraion to augment and refresh immune responses. As a monotherapy, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches.



HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.

In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers. The Phase 1/2 clinical trial for HB-201 was initiated in December 2019. The HB-202 IND application was cleared by the FDA in June 2020.


Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:

MediaInvestors
Nina WaibelMatt Beck
Senior Director - CommunicationsExecutive Director - Investor Relations
nina.waibel@hookipapharma.commatthew.beck@hookipapharma.com

Primary Logo


[ Back To TMCnet.com's Homepage ]